Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” by StockNews.com

Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday.

Other research analysts have also recently issued research reports about the company. Piper Sandler reiterated an “overweight” rating and issued a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Truist Financial increased their price objective on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a research report on Thursday, April 11th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $37.00 price objective (up previously from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock traded up $1.20 during trading hours on Tuesday, hitting $35.94. 618,658 shares of the company were exchanged, compared to its average volume of 431,744. Collegium Pharmaceutical has a 1 year low of $20.83 and a 1 year high of $40.95. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. The business has a 50-day moving average of $36.97 and a 200-day moving average of $31.11. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 30.46 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The business had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. As a group, analysts expect that Collegium Pharmaceutical will post 5.63 EPS for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Several large investors have recently bought and sold shares of COLL. Pacer Advisors Inc. grew its holdings in Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after purchasing an additional 883,380 shares during the last quarter. Penn Capital Management Company LLC acquired a new stake in Collegium Pharmaceutical in the fourth quarter valued at $9,755,000. Assenagon Asset Management S.A. grew its holdings in Collegium Pharmaceutical by 178.1% in the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after purchasing an additional 272,565 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Collegium Pharmaceutical by 1,475.5% during the fourth quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after acquiring an additional 188,347 shares during the last quarter. Finally, Qube Research & Technologies Ltd boosted its stake in shares of Collegium Pharmaceutical by 713.3% during the third quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after acquiring an additional 111,394 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.